This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Jim Weterings, PhD
Vice President Research, RNA Therapeutics & Delivery at Sirnaomics


Jim has had a tight bond with Oligonucleotides since 2002, performing research on PNA (conjugates) in the van Boom group at Leiden University, the Netherlands and targeted SSO conjugates at Prosensa. During his Ph.D at Leiden University he synthesized and studied CpG Oligonucleotide and other TLR ligand containing conjugates. At Cenix BioScience in Belgium/Germany, he developed targeted siRNA conjugates for CNS delivery. And at Cristal Therapeutics, the Netherlands he led various projects on the (targeted) nanomedicine delivery of oligonucleotide in oncology. In 2019 he joined AstraZeneca in Sweden, to further the advancement of (targeted) oligonucleotide therapeutics. In December 2022, Jim joined Sirnaomics, USA where he now serves as Vice President R&D USA, driving efforts to deliver RNAi Therapeutics using GalNAc and Peptide Nanoparticle platforms.

Agenda Sessions

  • GalAhead™ muRNA: A Proprietary GalNAc-RNAi Therapeutic Platform for Simultaneous Downregulation of Multiple Genes